Breast cancer is the most frequent cancer in women and the second cause of cancer-related deaths in women in Poland. Treatment is a multistage process, in which chemotherapy, radiotherapy, endocrine therapy and molecularly targeted therapy may be taken into consideration. This is description of the patient with metastatic breast cancer who during the using of fulvestrant has been reached the long-lasting clinical response. Rak piersi jest najczęściej występującym nowotworem u kobiet w Polsce oraz stanowi drugą przyczynę umieralności na nowotwory złośliwe u płci żeńskiej. Leczenie raka piersi jest procesem wieloetapowym, podczas którego stosowana może być chemioterapia, radioterapia, leczenie hormonalne oraz terapie celowane. W pracy przedst...
Despite the improvement in early detection and new therapeutic agents breast cancer remains the most...
With constant improvement of medicine we can diagnose and treat breast cancer in more and more effec...
A long-term survival of 45-year old patient with primary metastatic prostate cancer treated with var...
Breast cancer is the most common cancer among Polish women. Every year around 5000 women dies due to...
Breast cancer is the most common caner occurring in women in Poland.Hormone therapy in palliative tr...
Rak piersi jest najczęstszym kobiecym nowotworem złośliwym, w związku z czym stanowi bardzo istotny ...
Breast cancer is the most common cancer between women. It is the most common cancer among residents ...
Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women wit...
Breast cancer is the most common malignancy of women. Progress in screening mammography and adjuvant...
Breast cancer is the most common women neoplasm. Despite standard primary treatment, there are quite...
The choice of treatment modality in metastatic breast cancer depends on an age, performance status o...
Anthracyclines are drugs characterised by high efficacy in the treatment of patients with metastatic...
Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatmen...
Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant thera...
Hormone receptor-positive breast cancer is the most common subtype of breast cancer in all the stage...
Despite the improvement in early detection and new therapeutic agents breast cancer remains the most...
With constant improvement of medicine we can diagnose and treat breast cancer in more and more effec...
A long-term survival of 45-year old patient with primary metastatic prostate cancer treated with var...
Breast cancer is the most common cancer among Polish women. Every year around 5000 women dies due to...
Breast cancer is the most common caner occurring in women in Poland.Hormone therapy in palliative tr...
Rak piersi jest najczęstszym kobiecym nowotworem złośliwym, w związku z czym stanowi bardzo istotny ...
Breast cancer is the most common cancer between women. It is the most common cancer among residents ...
Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women wit...
Breast cancer is the most common malignancy of women. Progress in screening mammography and adjuvant...
Breast cancer is the most common women neoplasm. Despite standard primary treatment, there are quite...
The choice of treatment modality in metastatic breast cancer depends on an age, performance status o...
Anthracyclines are drugs characterised by high efficacy in the treatment of patients with metastatic...
Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatmen...
Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant thera...
Hormone receptor-positive breast cancer is the most common subtype of breast cancer in all the stage...
Despite the improvement in early detection and new therapeutic agents breast cancer remains the most...
With constant improvement of medicine we can diagnose and treat breast cancer in more and more effec...
A long-term survival of 45-year old patient with primary metastatic prostate cancer treated with var...